"Microdose Eye Droppers Cut Adverse Events, Costs" - Kevin Kunzmann
A microdose delivery system for eye drop therapies may be an improvement in treatment efficacy and costs. A team of researchers from the New York Eye and Ear Infirmary of Mount Sinai showed that a microdose delivery system, while delivering less than four times the amount of drug as a conventional eye dropper, achieved comparable treatment in patients. Tsontcho A. Ianchulev, MD, MPH, professor of ophthalmology at the Icahn School of Medicine at Mount Sinai and director of the ophthalmic innovation and technology program at the New York Eye and Ear Infirmary of Mount Sinai, believes health care officials have found a viable technology to “transform the 100-year old eyedropper paradigm.” Additional clinical trials to evaluate the technology’s treatment of glaucoma and pupil dilation are expected to begin in the next year, Dr. Ianchulev said. He believes the method could expand to treatments for DE, allergic eye disease, and infections.
- Tsontcho A. Ianchulev, MD, MPH, Professor, Ophthalmology, Icahn School of Medicine at Mount Sinai, Director, Ophthalmic Innovation and Technology, New York Eye and Ear Infirmary of Mount Sinai
Additional coverage: